Earnings Update: Here’s Why Analysts Just Lifted Their Ocumension Therapeutics (HKG:1477) Price Target To HK$9.27
As you might know, Ocumension Therapeutics (HKG:1477) last week released its latest interim, and things did not turn out so great for shareholders. Revenues missed expectations somewhat, coming in at CN¥294m, but statutory earnings fell catastrophically short, with a loss of CN¥0.17 some 42% larger than what the analysts had predicted. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there’s been a strong change in the company’s prospects, or if it’s business as usual. Readers will be glad to know we’ve aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Ocumension Therapeutics after the latest results.
